Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

21.44 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Reports Mixed Q2 2025 Results: Earnings Beat, Revenue Miss ↗

August 05, 2025

Amneal Pharmaceuticals (AMRX) reported mixed Q2 2025 results, with EPS beating estimates but revenue missing. Shares dipped slightly as investors weighed strong profitability against softer sales....

Via Chartmill

Topics Earnings

Amneal (NASDAQ:AMRX) Misses Q2 Sales Targets

August 05, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) fell short of the market’s revenue expectations in Q2 CY2025 as sales rose 3.2% year on year to $724.5 million. On the other hand, the...

Via StockStory

Amneal Reports Second Quarter 2025 Financial Results

August 05, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

A Peek at Amneal Pharmaceuticals's Future Earnings ↗

August 04, 2025

Via Benzinga

Amneal Earnings: What To Look For From AMRX

August 03, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings this Tuesday before the bell. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence Government World Trade

Q1 Earnings Highs And Lows: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks

July 28, 2025

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AMRX) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032

July 21, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results

July 21, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

3 Profitable Stocks with Warning Signs

July 21, 2025

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Via StockStory

Amneal to Report Second Quarter 2025 Results on August 5, 2025

July 09, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

1 Small-Cap Stock to Consider Right Now and 2 to Keep Off Your Radar

July 08, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

Topics Supply Chain

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

June 25, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

June 12, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris? ↗

June 06, 2025

Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook.

Via Benzinga

3 of Wall Street’s Favorite Stocks in the Doghouse

June 05, 2025

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...

Via StockStory

Topics Intellectual Property

Amneal Recalls Three Lots Of UTI Drug Over Concerns of Microbial Contamination: Retail Sticks To Bearish Territory ↗

June 04, 2025

The observance of black spots was reported in a product quality complaint, the U.S. FDA said, while noting that oral products contaminated with Aspergillus may result in serious and life-threatening...

Via Stocktwits

Topics Artificial Intelligence Product Recall

Amneal to Participate at Upcoming Investor Conferences in June

May 29, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

AMRX Q1 Earnings Call: Miss on Revenue, Margin Expansion, and Product Pipeline Progress

May 16, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 5.5% year on year to $695.4 million. On the other hand, the...

Via StockStory

Topics Supply Chain

Amneal Gets FDA Nod For Self-Administrable Migraine Injection ↗

May 15, 2025

The company said the injection is the first and only dihydroergotamine (DHE) autoinjector for treating migraine and cluster headaches.

Via Stocktwits

Topics Data Breach

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

May 15, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

3 Russell 2000 Stocks in Hot Water

May 13, 2025

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher...

Via StockStory

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.

May 08, 2025

From Amneal Pharmaceuticals LLC

Via GlobeNewswire

3 Value Stocks in Hot Water

May 08, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

Via StockStory

Topics Supply Chain

3 Small-Cap Stocks Facing Headwinds

May 07, 2025

Via StockStory

Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson's Drug But Q1 Earnings Are Mixed ↗

May 02, 2025

Amneal Pharmaceuticals reported first-quarter 2025 adjusted earnings per share of 21 cents, up from 14 cents a year ago.

Via Benzinga

Amneal (NASDAQ:AMRX) Misses Q1 Sales Targets, Stock Drops 11.3%

May 02, 2025

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 5.5% year on year to $695.4 million. On the other hand, the company’s...

Via StockStory

Amneal Reports First Quarter 2025 Financial Results

May 02, 2025

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Earnings Scheduled For May 2, 2025 ↗

May 02, 2025

Via Benzinga

Examining the Future: Amneal Pharmaceuticals's Earnings Outlook ↗

May 01, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.